Prostate specific membrane antigen (PSMA) is a transmembrane glycoprotein
which is almost expressed in all prostate cancers. The expression of PSMA in metastatic hormone-refractory prostate cancer is significantly increased. Radioimmunotherapy combined radionuclide with monoclonal antibody is a kind of targeted cancer therapy. This review will summarize the progress of radioimmunotherapy targeting PSMA.
Theranostics of targeted PSMA: application and progress
Initial clinical study of a novel prostate cancer imaging agent, 68 Ga-PSMA-4PY
Clinical value of 99mTc-PSMA SPECT/CT in detection of prostate cancer
Intratumoural and peritumoural mpMRI-based Delta-radiomics model for the prediction of the response to androgen deprivation therapy in prostate cancerLI Rong1, WANG Ting1, LÜ Hong2, LIU Xiaohang1, ZHOU Liangping1, GU Yajia1, ZHOU Bingni1
Evaluation of prostate cancer across different treatment stages using 18F-FDG PET imaging
Related Author
ZHANG Zhaoqi
ZHAO Xinming
ZHANG Xiaojun
LIU Huanhuan
LIU Yachao
WANG Ruimin
ZHANG Jinming
HU Silong
Related Institution
Department of Radiotherapy, Fudan University Shanghai Cancer Center
Center for Biomedical Imaging, Fudan University
Shanghai Engineering Research Center for Molecular Imaging Probes
Department of Oncology, Shanghai Medical College, Fudan University
Shanghai Proton and Heavy Ion Center, Fudan University Shanghai Cancer Center